Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate in asthma. A safety perspective

P G Bardin1, D J Fraenkel, R W Beasley

  • 1Immunopharmacology Group, University Medicine, Southampton General Hospital, England.

Drug Safety
|September 1, 1993
PubMed
Summary

Low-dose methotrexate may offer steroid-sparing benefits for severe asthma patients, potentially preventing long-term lung function decline. However, careful monitoring is crucial due to possible adverse effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abnormal vocal cord movement in patients with and without airway obstruction and asthma symptoms.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2016
Same author

Vocal cord dysfunction: asking the right questions.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2015
Same author

What's in a name? Expiratory tracheal narrowing in adults explained.

Clinical radiology·2013
Same author

Proportional classifications of COPD phenotypes.

Thorax·2008
Same author

Hygiene hypothesis, allergy and BCG: a dirty mix?

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2008
Same author

Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis.

Allergy·2007

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Asthma involves inflammation, driving interest in non-steroidal anti-inflammatory treatments.
  • Treating allergic inflammation may prevent long-term asthma consequences and pulmonary function decline.
  • Methotrexate (MTX) possesses potent anti-inflammatory properties, making it a potential asthma therapeutic candidate.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of low-dose methotrexate in severe asthma management.
  • To assess methotrexate's potential as a steroid-sparing agent in asthma patients.

Main Methods:

  • Review of non-comparative and placebo-controlled studies investigating low-dose methotrexate in severe asthma.
  • Analysis of reported benefits, including steroid-sparing effects, and adverse events.

Main Results:

  • Studies suggest methotrexate offers steroid-sparing benefits in severe asthma.
  • Generally mild adverse events were observed in up to one-third of patients.
  • Rare, potentially life-threatening pulmonary, hepatic, and hematological adverse effects are a concern.

Conclusions:

  • Methotrexate can be considered as an adjunct therapy for severe asthma patients requiring >10mg daily prednisolone and experiencing unacceptable steroid side effects.
  • Treatment should be initiated by experienced physicians with close monitoring of safety parameters.
  • Potential benefits must be weighed against the risks of serious adverse events.

Related Experiment Videos